Rate of employers covering weight-loss drugs is flat, Cigna says

Cigna reports that employer coverage for GLP-1 obesity drugs remains flat year-over-year, with over 50% of large Evernorth clients offering coverage compared to 15-20% of smaller Cigna Healthcare clients. Despite this, demand and utilization are increasing, driven by the drugs' efficacy, but their high cost poses a significant barrier. This trend, alongside rising healthcare service costs, is prompting U.S. employers to anticipate cutting other benefits to manage premium increases (projected 6-7% in 2026 for a 9% total cost rise), highlighting the growing financial pressure these treatments exert on the healthcare system. Cigna has also capped patient out-of-pocket costs at $200/month for covered individuals via PBM add-ons.

Analysis

Cigna's recent commentary highlights a critical tension in the GLP-1 obesity drug market: while underlying patient and physician demand remains robust, employer coverage has plateaued year-over-year due to significant cost barriers. There is a clear segmentation in adoption, with over 50% of Cigna's large employer clients (via its Evernorth unit) providing coverage, compared to only 15-20% of its smaller employer clients. This disparity is driven by the high list prices of drugs like Wegovy and Zepbound, which approach $1,000 per month, and employer concerns over return on investment, particularly in industries with high employee turnover. The financial pressure is systemic, with U.S. employers now projecting the need to cut other benefits to accommodate a 9% rise in total healthcare costs and limit premium increases to 6-7% by 2026. Cigna's strategic response, capping out-of-pocket costs at $200 per month for some members, positions its pharmacy benefit management (PBM) unit as a key intermediary attempting to manage affordability, but the core issue of high drug prices constraining broader market access persists.

Key Decisions for Investors

• For investors in GLP-1 manufacturers like Eli Lilly and Novo Nordisk, the continued high demand is fundamentally bullish, but the flat employer coverage rate signals a potential ceiling on near-term growth until pricing or reimbursement models evolve; monitor employer adoption trends and any signs of price negotiations closely.
• Investors in Cigna should view its position as both an opportunity and a risk; successful management of GLP-1 costs through its Evernorth PBM could enhance its value proposition to employers, but it also exposes the company to margin pressure if it cannot effectively control these high-cost claims.
• The projection that employers may cut other health benefits to afford obesity drugs is a key forward-looking indicator; investors should assess potential second-order impacts, such as headwinds for companies offering supplemental or voluntary benefits that may be deemed more discretionary in a cost-constrained environment.